Altimmune Inc…announced today new analyses from its IMPACT Phase 2b trial showing pemvidutide treatment resulted in improvements across multiple non-invasive tests for metabolic dysfunction-associated steatohepatitis and ﬁbrosis at 24 weeks.

pemvidutide (ALT-801) - Altimmune

May 27, 2026